$ZFGN Up 15% AH Positive Topline Phase 1 Clinical Trial ZGN-
Post# of 1460
(Total Views: 4457)
Posted On: 05/05/2017 1:48:18 AM
Zafgen today announced positive topline data from its Phase 1 clinical trial of ZGN-1061, the Company's second generation MetAP2 inhibitor. ZGN-1061 demonstrated rapid drug absorption and clearance in line with pre-specified criteria established for the molecule, and was well-tolerated and safe, with no evidence of prothrombotic effects. Patients in the clinical trial experienced mean weight loss of up to approximately one pound per week.
Results Support Advancement to Phase 2 Clinical Trial in Patients with Type 2 Diabetes in the Second Half of This Year
Results Support Advancement to Phase 2 Clinical Trial in Patients with Type 2 Diabetes in the Second Half of This Year
(0)
(0)Anavex Life Sciences Corp. (AVXL) Stock Research Links
Scroll down for more posts ▼